Elisabet Cruces
Companies & Markets Content Manager
Clarivate Analytics
Barcelona, Spain

Powered by



The mergers and acquisitions (M&A) activity in the Life Sciences sector in the fourth quarter of 2016 continued with similar tendency as the previous three quarters. In the last months of the year, 107 active M&A deals were reported by Clarivate Analytics Recap with a total disclosed value of $19.9 billion. The volume was approximately 17% less than the third quarter of 2016 (129 active M&A deals), which had reported a total disclosed value of $45.6 billion (including the $14.5 billion Medivation offer by Pfizer and several transactions with disclosed values higher than $3 billion).

DEAL ACTIVITY IN THE 4TH QUARTER FROM 2008 TO 2016
Looking into the same periods over the last eight years, the fourth quarter of 2016 did not reach the values of 2015, which included the $160 billion Pfizer and Allergan bid terminated in April, or 2014 with the completed $66 billion Actavis and Allergan merger (Figure 1). However, ...